Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-09-09
2008-09-09
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S133100, C530S300000
Reexamination Certificate
active
10129558
ABSTRACT:
Agents are provided which are capable of inhibiting the cell division cycle in a target cell of interest. The agents comprise first and second components, wherein the first component is a targeting moiety which is capable of directing the second component to the target cell of interest. The second component is capable of inhibiting the cell division cycle in the target cell of interest. The agents are preferably provided in the form of conjugates, and the second component is preferably a cytolethal distending toxin. Methods for the preparation of the agents, and the use thereof for treating proliferative cell disorders and intracellular pathogens are also provided.
REFERENCES:
patent: 4340535 (1982-07-01), Voisin et al.
patent: 5801191 (1998-09-01), Bressi et al.
patent: 5973116 (1999-10-01), Espenetos et al.
patent: 6824780 (2004-11-01), Devaux et al.
patent: 0815872 (1998-02-01), None
patent: WO 92/15327 (1992-09-01), None
patent: WO 94/21300 (1994-09-01), None
patent: WO 96/41608 (1996-12-01), None
patent: WO 97/33908 (1997-09-01), None
Jang et al. (FEBS Letters 2004; 560: 81-85).
Counis M.F. and Torriglia A. (Biochem. Cell Biol. 2000; 78: 405-414).
Krishnamurthy et al. (Current Science 2000: 79; 1169-1181).
Comayras et al. (Infection and Immunity 1997; 5088-5095).
Kreitman (Curr Opin. Immunol. Oct. 1999; 11 (5): 570-578).
Hinman, et al. A Membrane-Lytic Immunoconjugate Selective for Human Tumor T-Lymphocytes. International Journal of Immunopharmacology 20, pp. 467-478 (1998).
Jiang, et al. An Anti-CD19 Antibody Coupled to a Tetanus Toxin Peptide Induces Efficient Fas Ligand (FasL)-Medicated Cytotoxicity of a Transformed Human B Cell Line By Specific CD4+ T Cells. Clin. Exp. Immunol., vol. 114, pp. 173-178 (1998).
Beli{hacek over (c)}i{hacek over (c)}-Kol{hacek over (s)}ek. An Immunotoxin Constructed by Conjugating Equinatoxin II, a Lethal and Cytolytic Polypeptide, to Immunoglobylin G+. Acta. Pharm., vol. 43, pp. 147-150 (1993).
Dunn, et al. Antigen Binding and Cytotoxic Properties of a Recombinant Immunotoxin Incorporating the Lytic Peptide, Melittin. Immunotechnology, vol. 2, pp. 229-240 (1996).
Kolonin, et al., Targeting Cyclin-Dependent Kinases inDrosophilaWith Peptide Aptamers. Proc. Natl. Acad. Sci, vol. 95, pp. 14266-14271, Nov. 1998.
Huang, et al., Activation of CDC 25 Phosphatase and CDC 2 Kinase Involved in GL331-Induced Apoptosis. Cancer Research 57, pp. 2974-2978, Jul. 1997.
Comayras, et al.,Escherichia coliCytolethal Distending Toxin Blocks the HeLa Cell Cycle at the G2/M Transition by Preventing cdc2 Protein Kinase Dephosphorylation and Activation. Infection and Immunity, vol. 65, No. 12, pp. 5088-5095, Dec. 1997.
Charlton Susan
Henderson Ian
Purdy Desmond
Fetterolf Brandon J
Health Protection Agency
Hodgson & Russ LLP
LandOfFree
Use of lytic toxins and toxin conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of lytic toxins and toxin conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of lytic toxins and toxin conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3947613